Combination Chemotherapy for Non-Hodgkin's Lymphoma
Author Information
Author(s): H.S. Dhaliwal, A.Z.S. Rohatiner, W. Gregory, M.A. Richards, P.W.M. Johnson, J.S. Whelan, C.J. Gallagher, J. Matthews, T.S. Ganesan, M.J. Barnett, J.H. Waxman, A.G. Stansfeld, P.F.M. Wrigley, M.L. Slevin, J.S. Malpas, T.A. Lister
Primary Institution: ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK
Hypothesis
Can a combination chemotherapy regimen improve outcomes for patients with intermediate and high-grade non-Hodgkin's lymphoma?
Conclusion
The study found that combination chemotherapy led to a clinical remission in 64% of patients, with significant factors affecting remission duration and survival.
Supporting Evidence
- Clinical remission was achieved in 70 out of 110 evaluable patients.
- Complete remission was noted in 45 patients, while 25 achieved good partial remission.
- Hyponatremia and hypoalbuminaemia correlated adversely with achievement of complete remission.
- Advanced age was a significant predictor for remission duration.
- Overall survival was 42% at 8 years.
Takeaway
Doctors used a special mix of medicines to help people with a type of cancer called non-Hodgkin's lymphoma, and many of them got better.
Methodology
Patients received a combination of Doxorubicin, Cyclophosphamide, Vincristine, Prednisolone, and Methotrexate with leucovorin rescue, along with CNS prophylaxis.
Potential Biases
The study may have included a large proportion of patients with poor prognostic factors, which could affect the results.
Limitations
The study had a treatment-related mortality of 20%, and many patients had poor prognostic factors.
Participant Demographics
{"gender":{"male":71,"female":39},"age":{"median":54,"range":"15-79"}}
Statistical Information
P-Value
0.0007
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website